Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 3;24(1):246.
doi: 10.1186/s12876-024-03334-4.

Patient-reported symptoms and burden of eosinophilic esophagitis: evidence from real-world clinical practice

Xiao Xu  1   2 , Justin Kwiatek  3 , James Siddall  4 , Eduardo Genofre  5 , Heide Stirnadel-Farrant  6 , Rohit Katial  3
Affiliations

Patient-reported symptoms and burden of eosinophilic esophagitis: evidence from real-world clinical practice

Xiao Xu et al. BMC Gastroenterol. .

Abstract

Background: Eosinophilic esophagitis is a chronic inflammatory disorder of the esophagus. This real-world study used patient and physician surveys to describe the clinical characteristics and disease burden of eosinophilic esophagitis-overall and in a subgroup of patients with dysphagia despite treatment.

Methods: Data analyzed in this study were collected in 2020 from US and EU patients with eosinophilic esophagitis. Eligible patients were aged ≥ 12 years with a diagnosis of eosinophilic esophagitis, had an esophageal count of ≥ 15 eosinophils/high-power field at diagnosis, and were currently prescribed treatment for eosinophilic esophagitis.

Results: Overall, 1001 patients were included, of whom 356 (36%) had dysphagia despite treatment. Demographics and clinical characteristics were similar in both populations. The severity of eosinophilic esophagitis was mild in more patients overall (69%) versus those with dysphagia despite treatment (48%). Patient disease history was similar in both populations, with some exceptions: common patient-reported symptoms were dysphagia (70% and 86%) and heartburn/acid reflux (55% and 49%), and common physician-reported symptoms were dysphagia (75% and 91%) and food impaction (46% and 52%). Treatment history was similar in both populations; overall, the most common treatments were proton pump inhibitors (83%) and topical corticosteroids (51%). Patients reported slightly more days with symptoms, higher impacts on activities of daily living, and slightly higher anxiety or depression in the dysphagia-despite-treatment population versus the overall population.

Conclusions: Eosinophilic esophagitis presents severe symptoms and comorbidities that substantially impact patients' well-being and quality of life. Greater awareness of and novel treatments for eosinophilic esophagitis are needed.

Keywords: Disease burden; Eosinophilic esophagitis; Health-related quality of life; Inflammatory disease; Real-world evidence.

PubMed Disclaimer

Conflict of interest statement

Yes - X.X., J.K., R.K., E.G., and H.S.-F. are or were employees of AstraZeneca at the time of this study and may own stock. J.S. is an employee of Adelphi Real World, which received funding from AstraZeneca to conduct this analysis.

Figures

Fig. 1
Fig. 1
Patient population flowchart. EoE, eosinophilic esophagitis; eos/hpf, eosinophils per high-power field
Fig. 2
Fig. 2
Patient journey from the onset of EoE symptoms to diagnosis (a) overall and (b) in patients with dysphagia despite treatment. EoE, eosinophilic esophagitis; HCP, health care provider; PCP, primary care provider
Fig. 3
Fig. 3
Seven-day symptom burden
Fig. 4
Fig. 4
Seven-day impact on activities of daily living (a) overall and (b) in patients with dysphagia despite treatment.a EoE, eosinophilic esophagitis. aNumbers may not sum to 100% owing to rounding
Fig. 5
Fig. 5
EQ-5D-3L utility domain responses (a) overall and (b) in patients with dysphagia despite treatment.a EQ-5D-3L, EuroQol 5-dimension 3-level. aNumbers may not sum to 100% owing to rounding
See this image and copyright information in PMC

References

    1. Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108(5):679–92. 10.1038/ajg.2013.71 - DOI - PubMed
    1. Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J. 2017;5(3):335–58.10.1177/2050640616689525 - DOI - PMC - PubMed
    1. Pokrzywinski RM, Harding G, Brooks A, Goodwin B, Williams J. Documenting the journey of patients with eosinophilic esophagitis and the impact of the disease on patients and their caregivers: a cross-sectional, qualitative research study. Adv Ther. 2020;37(10):4458–78. 10.1007/s12325-020-01463-2 - DOI - PubMed
    1. Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health-Care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol. 2015;110(5):626–32. 10.1038/ajg.2014.316 - DOI - PMC - PubMed
    1. Bredenoord AJ, Patel K, Schoepfer AM, et al. Disease Burden and Unmet need in Eosinophilic Esophagitis. Am J Gastroenterol. 2022;117(8):1231–41. 10.14309/ajg.0000000000001777 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources